Epidemiology of malaria and elimination prospects in Maghreb Countries.

BACKGROUND: Faced with the challenges of immigration, the opening of the Trans-Saharan road and the increase in the volume of trade with sub-Saharan Africa, there is a steady increase in the number of malaria cases. An introduction of the disease in the Maghreb is possible. OBJECTIVE: The general objective is to take stock of the epidemiological situation and the malaria control strategy in the Maghreb countries. METHODS: This is a synthesis of data from a literature search on: PubMed (publications), International and national reports (epidemiology and strategies). RESULTS: In 1979, Tunisia became the second Maghreb country to eliminate malaria after Libya (the last local case in 1973). In 1997, when 76 cases were recorded, Morocco embarked on a new national strategy aimed at the elimination of indigenous malaria by the end of 2005. In Algeria, after a phase of control by existence of P. vivax and P. malaria microspheres, the country is in the maintenance phase and no cases were recorded between 2013 and 2016. In Mauritania, even though malaria transmission is generally low, this parasitosis remains a problem public health. And the strategies of struggle and the contribution of scientific research remain below expectations. CONCLUSION: With the exception of Mauritania, the countries of the Great Arab Maghreb have practically eradicated malaria, even though the maintenance phase is underway in Algeria and cases imported from sub-Saharan Africa continue to be registered.

Malaria-associated morbidity during the rainy season in Saharan and Sahelian zones in Mauritania.

Reliable epidemiological data based on laboratory-confirmed cases are scarce in Mauritania. A large majority of reported malaria cases are based on presumptive clinical diagnosis. The present study was conducted to establish a reliable database on malaria morbidity among febrile paediatric and adult patients consulting spontaneously at public health facilities in Nouakchott, situated in the Saharan zone, and in Hodh Elgharbi region in the Sahelian zone in south-east Mauritania during the peak transmission periods. Giemsa-stained thin and thick films were examined under the microscope, and the parasite density was determined according to the procedures recommended by the World Health Organization. Microscopy results were confirmed by rapid diagnostic test for malaria. A total of 1161 febrile patients (498 in Nouakchott and 663 in Hodh Elgharbi region) were enrolled during two successive peak transmission periods in 2009 and 2010. In Nouakchott, 253 (50.8%) febrile patients had positive smears (83% Plasmodium vivax monoinfections and 17% Plasmodium falciparum monoinfections). In Hodh Elgharbi, 378 of 663 patients (57.0%) were smear-positive, mostly due to P. falciparum monoinfections (96.6%). Unlike in Nouakchott, mixed P. falciparum-P. vivax infections, as well as P. vivax, P. ovale, and P. malariae monoinfections, were also observed at a very low prevalence in southern Mauritania. In Nouakchott, malaria occurred more frequently (P<0.05) with higher slide positivity rates (42-53%) among children aged >5 years old and adults than in young children aged <5 years old in both 2009 and 2010. In Hodh Elgharbi, high slide positivity rates (60.9-86.2%) were observed in all age groups in 2010, and there was no significant trend (P>0.05) in relation with age groups. The present study confirmed the predominance of P. falciparum in southern Mauritania reported in previous studies. The presence of P. vivax in Nouakchott is a new epidemiological reality that requires an urgent adoption of novel strategies for parasitological and vector control to combat urban malaria. Moreover, the present study provides evidence-based data on malaria burden in two regions in Mauritania that may serve as a springboard to establish and develop a national surveillance system of malaria epidemiology.

Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania.

BACKGROUND: In 2006, the Mauritanian Ministry of Health adopted a new therapeutic strategy based on the systematic use of artemisinin-based combination therapy (ACT), artesunate-amodiaquine and artemether-lumefantrine, for the first- and second-line treatment of uncomplicated malaria, respectively, regardless of Plasmodium spp. In the Saharan zone of the country, recent studies have shown that Plasmodium vivax largely predominates over Plasmodium falciparum. Anti-malarial drug response of P. vivax has not been evaluated in Mauritania. The aim of the present study was to evaluate the clinical efficacy and tolerance of chloroquine to treat P. vivax malaria in Mauritanian patients. METHODS: Plasmodium vivax-infected patients aged > 6 months old were enrolled in Nouakchott and Atar in September-October 2013. Chloroquine was administered at the standard dose of 25 mg base/kg body weight over three days. Patients were followed until day 28, according to the standard 2009 World Health Organization protocol. RESULTS: A total of 128 patients (67 in Nouakchott and 61 in Atar) were enrolled in the study. Seven patients (5.5%) were either excluded or lost to follow-up. Based on the per protocol analysis, chloroquine efficacy (adequate clinical and parasitological response) was 100%. Treatment was well-tolerated. One patient was excluded on day 1 due to urticaria and treated with artesunate-amodiaquine. CONCLUSIONS: Although the current national treatment guideline recommends artesunate-amodiaquine for the first-line treatment of uncomplicated malaria, including P. vivax malaria, chloroquine may still have an important role to play in anti-malarial chemotherapy in Mauritania. Further epidemiological studies are required to map the distribution of P. vivax and P. falciparum in the country.

Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania.

BACKGROUND: A regular evaluation of therapeutic efficacy in sentinel sites and a system of surveillance are required to establish treatment guidelines and adapt national anti-malarial drug policy to the rapidly changing epidemiology of drug-resistant malaria. The current anti-malarial treatment guideline in Mauritania, officially recommended since 2006, is based on artemisinin-based combination therapy. The aim of the present study was to evaluate clinical efficacy and tolerance of artesunate-amodiaquine, the first-line treatment for acute uncomplicated malaria, in Mauritanian paediatric and adult patients to validate its continued use in the country. METHODS: Plasmodium falciparum-infected symptomatic patients aged > six months were enrolled in Kobeni and Timbedra in southern Mauritania in September to October 2013. Co-formulated artesunate-amodiaquine was administered at the recommended dose over three days. Patients were followed until day 28. Parasitological and clinical response was classified according to the standard 2009 World Health Organization protocol. RESULTS: A total of 130 patients (65 in Kobeni and 65 in Timbedra) were enrolled in the study. Seventeen patients (13.1%) were either excluded (before PCR correction) or lost to follow-up. Based on the per protocol analysis, artesunate-amodiaquine efficacy (i.e., the proportion of adequate clinical and parasitological response) was 96.6% in Kobeni and 98.2% in Timbedra before PCR correction. Late clinical failure was observed in two patients in Kobeni and one patient in Timbedra. After PCR correction, the efficacy rate in the two study sites was 98.2%. On day 3, all patients were afebrile and had negative smears. Treatment was well tolerated. CONCLUSIONS: Artesunate-amodiaquine is well tolerated and highly efficacious for the treatment of uncomplicated P. falciparum malaria. In the majority of patients, fever and parasitaemia were rapidly cleared before day 3. The results support the national anti-malarial drug guideline for a continued use of artesunate-amodiaquine as a first-line drug for uncomplicated malaria in southern Mauritania.

Polymorphism of the merozoite surface protein-1 block 2 region in Plasmodium falciparum isolates from Mauritania.

BACKGROUND: The genetic diversity of Plasmodium falciparum has been extensively studied in various parts of the world. However, limited data are available from Mauritania. The present study examined and compared the genetic diversity of P. falciparum isolates in Mauritania. METHODS: Plasmodium falciparum isolates blood samples were collected from 113 patients attending health facilities in Nouakchott and Hodh El Gharbi regions. K1, Mad20 and RO33 allelic family of msp-1 gene were determined by nested PCR amplification. RESULTS: K1 family was the predominant allelic type carried alone or in association with Ro33 and Mad20 types (90%; 102/113). Out of the 113 P. falciparum samples, 93(82.3%) harboured more than one parasite genotype. The overall multiplicity of infection was 3.2 genotypes per infection. There was no significant correlation between multiplicity of infection and age of patients. A significant increase of multiplicity of infection was correlated with parasite densities. CONCLUSIONS: The polymorphism of P. falciparum populations from Mauritania was high. Infection with multiple P. falciparum clones was observed, as well as a high multiplicity of infection reflecting both the high endemicity level and malaria transmission in Mauritania.

A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil.

BACKGROUND: Praziquantel at 40 mg/kg in a single dose is the WHO recommended treatment for all forms of schistosomiasis, but 60 mg/kg is also deployed nationally. METHODOLOGY/PRINCIPAL FINDINGS: Four trial sites in the Philippines, Mauritania, Tanzania and Brazil enrolled 856 patients using a common protocol, who were randomised to receive praziquantel 40 mg/kg (n  =  428) or 60 mg/kg (n  =  428). While the sites differed for transmission and infection intensities (highest in Tanzania and lowest in Mauritania), no bias or heterogeneity across sites was detected for the main efficacy outcomes. The primary efficacy analysis was the comparison of cure rates on Day 21 in the intent-to-treat population for the pooled data using a logistic model to calculate Odd Ratios allowing for baseline characteristics and study site. Both doses were highly effective: the Day 21 cure rates were 91.7% (86.6%-98% at individual sites) with 40 mg/kg and 92.8% (88%-97%) with 60 mg/kg. Secondary parameters were eggs reduction rates (ERR), change in intensity of infection and reinfection rates at 6 and 12 months. On Day 21 the pooled estimate of the ERR was 91% in both arms. The Hazard Ratio for reinfections was only significant in Brazil, and in favour of 60 mg/kg on the pooled estimate (40 mg/kg: 34.3%, 60 mg/kg: 23.9%, HR  =  0.78, 95% CI  = [0.63;0.96]). Analysis of safety could not distinguish between disease- and drug-related events. 666 patients (78%) reported 1327 adverse events (AE) 4 h post-dosing. The risk of having at least one AE was higher in the 60 than in the 40 mg/kg group (83% vs. 73%, p<0.001). At 24 h post-dosing, 456 patients (54%) had 918 AEs with no difference between arms. The most frequent AE was abdominal pain at both 4 h and 24 h (40% and 24%). CONCLUSION: A higher dose of 60 mg/kg of praziquantel offers no significant efficacy advantage over standard 40 mg/kg for treating intestinal schistosomiasis caused by either S. mansoni or S. japonicum. The results of this study support WHO recommendation and should be used to inform policy decisions in the countries.